Dyslipidemia

Manesh Patel, MD, briefly addresses the mechanism of action of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

Dean Karalis, MD, provides his perspective on intensive LDL lowering in patients with risk for high cholesterol and related disorders.

The once-daily tablet is indicated for adult patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia

In this edition of Inside Cardiology, a trio of advisory board members discuss a series of case reports, upcoming and newly released therapies for lipid disorders, and use of telehealth for the management of patients.

Welcome to Inside Cardiology: Lipid Management 2021. This edition of Inside Cardiology features a discussion around lipidology led by Chief of Practical Cardiology's Editorial Advisory Board Guy Mintz, MD. Mintz is joined by fellow advisory board members Lucia Novak, CRNP, and Brett Nowlan, MD. In the first segment, panelists introduce themselves and examine the first case report in their 5-part discussion.

In this segment, panelists discuss their third and final case report. This case features a 63-year-old male classified as a very high-risk patient.

In this segment, panelists discuss their second case report. This case features a 60-year-old female classified as an extreme risk patient with diabetes.

Althera Pharmaceuticals announced the FDA approved rosuvastatin and ezetimibe (Roszet) as an adjunct to diet for lowering LDL-C in adults patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia.

High blood pressure at a younger age could forecast cardiovascular problems in adulthood.

Announced in a statement by the FDA on April 1, the PCKS9 inhibitor alirocumab is now indicated as an add-on therapy for the treatment of homozygous familial hypercholesterolemia.

Linda Hemphill, MD, shares her views on how familial hypercholesterolemia impacts the assessment of high-risk patients.

Norman Lepor, MD, FACC, FAHA, FSCAI, shares how he would identify and monitor patient populations at high risk for CV morbidity and mortality.

Researchers compare the NYHA class identifier with KCCQ-QS.

The analysis was less statistically powered when comparing sibling discordant.

In this column, Arnold Meshkov, MD, explores the history of the "Thrombus Hypothesis" and his experiences with thrombus in myocardial infarction as a practicing clinician.

Expert panel of cardiologists provide their perspective on the specific population that may be at a risk of developing hyperlipidemia.

Manesh Patel, MD, discusses the pathophysiology of the relationship between hypercholesterolemia and cardiovascular disease.

An analysis comparing propensity-matched data from 4k transgender is providing an updated overview of the risk profile for patients undergoing gender-affirming therapy compared to their cisgender counterparts.

The majority of previous studies have focused on this link in the male population.

Researchers test 3 different machine learning models to aid in expanding the number of variables needed to better predict outcomes.

An analysis of the REDUCE-IT trial suggests patients on statins who were also receiving icosapent ethyl reduced their risk of an ischemic stroke by an additional 36%.

A recent study found that time-restricted diets did not induce changes in blood pressure or lipid profiles, but did lead to reductions in weight loss.

Guidelines call for athletes to miss up 6 months of sports following a myocarditis diagnosis. How frequent is the condition in the era of a risk-driving pandemic?

Researchers see differences in how SARS-CoV-2 attacks the brain in comparison to the influenza virus that caused the 1918 pandemic.

There was no difference in rates of 30-day cardiac mortality and acute myocardial infarction between single troponin test recipients and serial troponin test recipients.